VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.8%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$237M
AUM Growth
-$4.18M
(-1.7%)
Cap. Flow
-$15.8M
Cap. Flow
% of AUM
-6.66%
Top 10 Holdings %
Top 10 Hldgs %
7.93%
Holding
416
New
61
Increased
247
Reduced
47
Closed
61
Top Buys
| 1 |
EOG Resources
EOG
|
$2.02M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.99M |
| 3 |
ConocoPhillips
COP
|
$1.85M |
| 4 |
Imperial Oil
IMO
|
$1.8M |
| 5 |
Reliance Steel & Aluminium
RS
|
$1.76M |
Top Sells
| 1 |
Ryman Hospitality Properties
RHP
|
$2.57M |
| 2 |
Western Midstream Partners
WES
|
$2.52M |
| 3 |
INN
Summit Hotel Properties
INN
|
$2.43M |
| 4 |
Brookfield Renewable
BEPC
|
$2.38M |
| 5 |
Grupo Aeroportuario del Pacifico
PAC
|
$2.16M |
Sector Composition
| 1 | Healthcare | 30.46% |
| 2 | Real Estate | 18.03% |
| 3 | Energy | 13.68% |
| 4 | Materials | 11.34% |
| 5 | Utilities | 10.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Viking Therapeutics
VKTX
$3.03B
| $283K | 0.12% |
44,755
+789
| +2% | +$4.99K |
|
252
Xencor
XNCR
$610M
| $282K | 0.12% |
6,543
+117
| +2% | +$5.04K |
|
|
TECX
253
Tectonic Therapeutic, Inc. Common Stock
TECX
$314M
| $282K | 0.12% |
1,854
+33
| +2% | +$5.02K |
|
254
Oxford Square Capital
OXSQ
$172M
| $281K | 0.12% |
60,656
-9,080
| -13% | -$42.1K |
|
255
BioXcel Therapeutics
BTAI
$55.2M
| $280K | 0.12% |
405
+7
| +2% | +$4.84K |
|
|
EVF
256
Eaton Vance Senior Income Trust
EVF
$101M
| $280K | 0.12% |
42,193
+4,301
| +11% | +$28.5K |
|
|
EFF
257
DELISTED
EATON VANCE FLOATING-RATE INCOME PLUS FUND
EFF
| $278K | 0.12% |
17,104
+2,866
| +20% | +$46.6K |
|
258
ALX Oncology
ALXO
$65.3M
| $277K | 0.12% |
3,758
+70
| +2% | +$5.16K |
|
|
BRW
259
Saba Capital Income & Opportunities Fund
BRW
$349M
| $276K | 0.12% |
29,723
+4,815
| +19% | +$44.7K |
|
260
RAPT Therapeutics
RAPT
$214M
| $275K | 0.12% |
1,548
+29
| +2% | +$5.15K |
|
261
Sarepta Therapeutics
SRPT
$1.96B
| $275K | 0.12% |
3,686
+96
| +3% | +$7.16K |
|
|
BCEL
262
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $274K | 0.12% |
17,856
+306
| +2% | +$4.7K |
|
|
OYST
263
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $274K | 0.12% |
14,995
+266
| +2% | +$4.86K |
|
264
Geron
GERN
$893M
| $273K | 0.12% |
172,591
+3,044
| +2% | +$4.82K |
|
265
XBiotech
XBIT
$89M
| $273K | 0.12% |
15,872
+288
| +2% | +$4.95K |
|
266
AnaptysBio
ANAB
$613M
| $269K | 0.11% |
12,476
+225
| +2% | +$4.85K |
|
267
Cue Biopharma
CUE
$59.9M
| $269K | 0.11% |
22,053
+393
| +2% | +$4.79K |
|
268
89bio
ETNB
$1.32B
| $269K | 0.11% |
11,351
+197
| +2% | +$4.67K |
|
269
Inovio Pharmaceuticals
INO
$148M
| $268K | 0.11% |
2,404
+42
| +2% | +$4.68K |
|
|
GMDA
270
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $267K | 0.11% |
33,042
+587
| +2% | +$4.74K |
|
|
ISEE
271
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $267K | 0.11% |
43,267
+758
| +2% | +$4.68K |
|
272
Arrowhead Research
ARWR
$4.02B
| $266K | 0.11% |
4,006
+68
| +2% | +$4.52K |
|
273
Syndax Pharmaceuticals
SNDX
$1.47B
| $264K | 0.11% |
11,828
+204
| +2% | +$4.55K |
|
|
KDMN
274
DELISTED
Kadmon Holdings, Inc.
KDMN
| $264K | 0.11% |
67,781
+1,187
| +2% | +$4.62K |
|
275
Gossamer Bio
GOSS
$668M
| $263K | 0.11% |
28,463
+500
| +2% | +$4.62K |
|